Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to evaluate its ready-to-use, room temperature-stable glucagon in patients with Type 1 diabetes who suffer from exercise-induced hypoglycemia (EIH). This is a critical step for the company as it looks to […]
TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for the treatment of inherited Epidermolysis Bullosa (EB). This trial marks a significant advancement in the quest for effective therapies for this challenging condition. The Phase 2 trial of AC-203 is […]
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate F351 in China. This decision follows a recommendation from an independent data monitoring committee (IDMC) based on positive efficacy results achieved to date. As of now, 175 out of the […]